CD30 is expressed in approximately 32-64% of PTCL-NOS, 43-63% of AITL, 100% of systemic ALCL and 46-80% of NKTCL, reflecting a biomarker with significant prevalence and thus utility in the population of PTCL (14, 103–105). This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.